AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer

News   Apr 06, 2012

 
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
 
 
FURTHER INFORMATION
 
 
 
 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE